Best Momentum Stocks to Buy for January 26th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 26:
PACCAR Inc PCAR: This truck manufacturer company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.1% over the last 60 days.
PACCAR Inc. Price and Consensus
PACCAR Inc. price-consensus-chart | PACCAR Inc. Quote
PACCAR's shares gained 22.5% over the last three months compared with the S&P 500’s advance of 18%. The company possesses a Momentum Score of A.
PACCAR Inc. Price
PACCAR Inc. price | PACCAR Inc. Quote
Inhibikase Therapeutics, Inc. IKT: This pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.
Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote
Inhibikase Therapeutics's shares gained 195.5% over the last three months compared with the S&P 500’s advance of 18%. The company possesses a Momentum Score of A.
Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote
PagerDuty, Inc. PD: This digital operations platform company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.1% over the last 60 days.
PagerDuty Price and Consensus
PagerDuty price-consensus-chart | PagerDuty Quote
PagerDuty's shares gained 21.8% over the last three months compared with the S&P 500’s advance of 18%. The company possesses a Momentum Score of B.
PagerDuty Price
PagerDuty price | PagerDuty Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PACCAR Inc. (PCAR) : Free Stock Analysis Report
PagerDuty (PD) : Free Stock Analysis Report
Inhibikase Therapeutics, Inc. (IKT) : Free Stock Analysis Report
